Circulating microRNA‑103a‑3p could be a diagnostic and prognostic biomarker for breast cancer

Abstract

Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell-free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR-103a-3p has been reported in several types of human cancer. However, the role of miR-103a-3p in BC remains unknown. A total of 112 patients with BC and 59 healthy controls were recruited into the present study. The expression level of serum miR-103a-3p was evaluated using reverse transcription-quantitative PCR. Receiver operating characteristic curves were utilized to calculate diagnostic accuracy. Survival curves were generated to analyze survival outcomes. It was found that circulating miR-103a-3p level was upregulated in patients with BC compared with that in healthy controls, and its expression was decreased following surgery. In addition, miR-103a-3p expression level was also associated with advanced clinicopathological features, including positive epidermal growth factor receptor 2 status, metastasis and an advanced TNM stage. The circulating serum miR-103a-3p level could be used to discriminate between patients with BC and the healthy controls prior to surgery using an area under curve [(AUC), 0.697; 95% confidence intervals (CI), 0.615-0.778], and distinguish patients with BC and metastasis from those without metastasis (AUC, 0.936; 95% CI, 0.892-0.980). In addition, high expression level of miR-103a-3p was associated with worse survival outcomes in patients with BC. In conclusion, the present study suggests that miR-103a-3p could be a potential non-invasive diagnostic and prognostic biomarker for BC. Materials and methodsClinical samples. A total of 112 women with BC, who were admitted and received treatment at the Cangzhou Central Hospital (Hebei, China) between

MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in Serum and Tissue: Potential Biomarkers in Sporadic Breast Cancer

“…Recently, miR-875 and miR-103a-3p were described as potential prognostic markers in BC patients. Nonetheless, the number of evaluated patients was quite limited, in addition to the absence of a second validation cohort ( Liu H. et al, 2022 ; Liu et al, 2022 X. ).…”

Potential utility of miRNAs for liquid biopsy in breast cancer

“…The downregulation of miR-329 in serum and tissue of patients with BC is associated with metastasis to lymph nodes while upregulation of miR-200 is correlated with metastasis to the brain, liver, and lung ( 84 ). Indeed, there are a number of studies that demonstrate the potency of certain miRNA utilization as BC biomarkers in various samples ( 56 , 86 – 93 ). Apparently, miRNAs maintain the healthy balance of signaling pathways for the normal function of the body.…”

“…miR-103a is suggested to be a biomarker for BC detection as its circulating levels are reported to be increased in patients with BC ( 86 , 210 ). Liu et al.…”

miRNAs as biomarkers in human diseases

“…In addition to diagnosis, miRNAs have also been utilised as novel biomarkers in the prediction of prognosis (Zhang et al, 2019;Sun et al, 2019) and integrating multiple miRNAs might be more effective than single ones to predict prognosis (He et al, 2019). It is suggested that miR-103a-3p might be a potential non-invasive diagnostic and prognostic biomarker (Liu et al, 2022). Moreover, hsa-miR-584-5p detected as tumor suppressor miRNA is a potential candidate biomarker for coronary artery diseases (Coban et al 2020).…”